Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
暂无分享,去创建一个
Jacques Fellay | Catia Marzolini | J. Fellay | C. Marzolini | D. Back | for the Swiss Hiv Cohort Study | David J Back | for the Swiss HIV Cohort Study | Emma R Meaden | E. R. Meaden
[1] H. Macdonald,et al. Developmentally regulated expression of P‐glycoprotein (multidrug resistance) activity in mouse thymocytes , 1995, European journal of immunology.
[2] M. Liscovitch,et al. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences , 2000, Glycoconjugate Journal.
[3] I. Roninson,et al. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.
[4] A. Schinkel,et al. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors , 2000, AIDS.
[5] I. Pastan,et al. Effect of ABC transporters on HIV‐1 infection: inhibition of virus production by the MDR1 transporter , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] J. Kigawa,et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.
[7] M. Battegay,et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.
[8] G. Plosker,et al. Nelfinavir , 2000, Drugs.
[9] U. Meyer,et al. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.
[10] D. Meijer,et al. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted , 1998, British journal of pharmacology.
[11] Alan S. Perelson,et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.
[12] U. Brinkmann,et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[13] U. Brinkmann,et al. Frequency of C3435T polymorphism of MDR1 gene in African people , 2001, The Lancet.
[14] G R Wilkinson,et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.
[15] D. Dormont,et al. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. , 2000, AIDS.
[16] Li,et al. Transport, metabolism and elimination mechanisms of anti-HIV agents. , 1999, Advanced drug delivery reviews.
[17] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[18] D. Middlemas,et al. Human Immunodeficiency Virus Protease Inhibitors Serve as Substrates for Multidrug Transporter Proteins MDR1 and MRP1 but Retain Antiviral Efficacy in Cell Lines Expressing These Transporters , 1998, Antimicrobial Agents and Chemotherapy.
[19] M. Relling,et al. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. , 2000, Molecular pharmacology.
[20] M. Relling,et al. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[21] D. Roden,et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.
[22] M. Fromm,et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.
[23] C. Cass,et al. Multidrug transporter p‐glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: Modulation with differentiation stage and during aging , 1995, American journal of hematology.
[24] G R Wilkinson,et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[25] J. Drewe,et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. , 1999, Molecular pharmacology.
[26] H. McLeod,et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. , 2001, Pharmacogenetics.
[27] J. Margolick,et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study , 2001, AIDS.
[28] G. Elizondo,et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity , 2000, Clinical pharmacology and therapeutics.
[29] A. Telenti,et al. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. , 2000, Journal of chromatography. B, Biomedical sciences and applications.
[30] S. Khoo,et al. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport , 2001, AIDS.
[31] J. A. Carrillo,et al. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. , 1998, Therapeutic drug monitoring.
[32] R. Kim,et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.
[33] M. Ingelman-Sundberg,et al. PCR-based genotyping for duplicated and deleted CYP2D6 genes. , 1996, Pharmacogenetics.
[34] J. Polli,et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[35] P. Borst,et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.